Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Daniel R. Chevallard purchased 54,945 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the transaction, the chief financial officer now directly owns 59,415 shares of the company’s stock, valued at $54,067.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Regulus Therapeutics Inc. (RGLS) traded up 0.91% during mid-day trading on Tuesday, reaching $1.11. 1,151,436 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $1.06 and its 200-day moving average price is $1.41. The stock’s market cap is $59.03 million. Regulus Therapeutics Inc. has a 12-month low of $0.86 and a 12-month high of $4.25.

TRADEMARK VIOLATION WARNING: “Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Daniel R. Chevallard Buys 54,945 Shares” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/25/regulus-therapeutics-inc-nasdaqrgls-cfo-daniel-r-chevallard-buys-54945-shares.html.

A number of research analysts recently weighed in on the stock. Wedbush reissued an “outperform” rating and set a $6.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, March 29th. ValuEngine lowered shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. BMO Capital Markets reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Monday, May 15th. Chardan Capital dropped their price target on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating on the stock in a research report on Tuesday, June 13th. Finally, Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $3.92.

Hedge funds have recently made changes to their positions in the stock. Tudor Investment Corp ET AL increased its stake in shares of Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the last quarter. South Dakota Investment Council increased its stake in shares of Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares during the last quarter. Wedbush Securities Inc. increased its stake in shares of Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 93,420 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the last quarter. 38.53% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.